US Patent

US8680124 — Treatment of cancers with acquired resistance to kit inhibitors

Method of Use · Assigned to Bayer Healthcare LLC · Expires 2030-06-02 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating cancers that have developed resistance to KIT inhibitors by administering a specific compound called DAST.

USPTO Abstract

The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide).

Drugs covered by this patent

chembl-chembl1946170 (REGORAFENIB)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1506`	—	chembl-chembl1946170

Patent Metadata

Patent number: US8680124
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-02
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Healthcare LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.